Article
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Cancer discovery - 1 Feb 2020
Smyth Lillian M, Piha-Paul Sarina A, Won Helen H, Schram Alison M, Saura Cristina, Loi Sherene, Lu Janice, Shapiro Geoffrey I, Juric Dejan, Mayer Ingrid A, Arteaga Carlos L, de la Fuente Macarena I, Brufksy Adam M, Spanggaard Iben, Mau-Sørensen Morten, Arnedos Monica, Moreno Victor, Boni Valentina, Sohn Joohyuk, Schwartzberg Lee S, Gonzàlez-Farré Xavier, Cervantes Andrés, Bidard François-Clement, Gorelick Alexander N, Lanman Richard B, Nagy Rebecca J, Ulaner Gary A, Chandarlapaty Sarat, Jhaveri Komal, Gavrila Elena I, Zimel Catherine, Selcuklu S Duygu, Melcer Myra, Samoila Aliaksandra, Cai Yanyan, Scaltriti Maurizio, Mann Grace, Xu Feng, Eli Lisa D, Dujka Melanie, Lalani Alshad S, Bryce Richard, Baselga José, Taylor Barry S, Solit David B, Meric-Bernstam Funda, Hyman David M
Abstract excerpt
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.